ArticleJournal of diabetes and metabolic disorders2025
Comparative effects of nano-curcumin versus curcumin on plasma levels of spexin and its gene expression in liver tissue, insulin resistance, lipid profile, and fasting blood glucose in type 2 diabetic rats.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trial
- Emerging roles of spexin in cardiovascular homeostasis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spexin is an adipokine secreted by various tissues, including white adipocytes and the brain. Its release is inversely associated with the state of energy storage. Curcumin (CUR), a polyphenolic substance extracted from turmeric, has been widely investigated for its beneficial effects, including the inhibition of oxidative stress and inflammation. Nano-curcumin (nCUR) is a novel preparation developed to enhance curcumin's absorption and therapeutic potency. This present study aimed to examine the comparative impacts of CUR and nCUR on plasma levels of Spexin, its gene expression in liver tissue, insulin resistance, lipid profiles, and fasting blood glucose (FBG) in type 2 diabetes mellitus (T2DM) rats. Methods: Twenty-four male Wistar rats were divided into four groups: A T2DM group receiving 200 mg/kg nCUR, a T2DM group receiving 200 mg/kg CUR, a T2DM group, and a control group. The rats in the T2DM groups developed diabetes through a high-fat and high-glucose diet, along with streptozotocin injection. Plasma levels of Spexin, FBG, insulin resistance, and lipid profile were assessed. Additionally, the Spexin gene expression in liver samples was evaluated using quantitative real-time PCR (qRT-PCR). Results: Both nCUR and CUR significantly improved insulin resistance, reduced FBG, and improved lipid levels in T2DM rats compared to the diabetic control rats (p < 0.05). Notably, nCUR demonstrated a more pronounced elevation in plasma Spexin levels and its gene expression in liver tissue than CUR. Conclusion: nCUR offers superior therapeutic benefits over CUR in managing T2DM, particularly in improving lipid metabolism, and Spexin regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.